Lupin Limited
LUPIN
Rangering i aksjer
#2103
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
Aksjekurs
$21.43
Sist synkronisert: 2026-10-21
Markedsverdi
$9.80B
Endring (1 dag)
0.14%
Endring (1 år)
-2.88%
Land
IN
Handel Lupin Limited (LUPIN)
Kategori
Healthcare
Inntekter for Lupin Limited (LUPIN)
Inntekter i Jun 2026 TTM: $3.30B
Ifølge de nyeste økonomiske rapportene til Lupin Limited er selskapets nåværende inntekter (TTM) $3.30B. I 2024 hadde selskapet inntekter på $2.40B en økning sammenlignet med inntektene i 2023, som var $2.03B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Lupin Limited fra 2004 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $3.30B | 24.28% |
| 2025 | $2.66B | 10.63% |
| 2024 | $2.40B | 18.51% |
| 2023 | $2.03B | -6.30% |
| 2022 | $2.16B | 4.34% |
| 2021 | $2.07B | 1.49% |
| 2020 | $2.04B | -3.36% |
| 2019 | $2.11B | -12.84% |
| 2018 | $2.42B | -9.52% |
| 2017 | $2.68B | 25.55% |
| 2016 | $2.13B | 4.23% |
| 2015 | $2.05B | -3.94% |
| 2014 | $2.13B | 20.07% |
| 2013 | $1.77B | 27.03% |
| 2012 | $1.40B | 9.08% |
| 2011 | $1.28B | 20.48% |
| 2010 | $1.06B | 42.91% |
| 2009 | $743.76M | 9.97% |
| 2008 | $676.32M | 45.59% |
| 2007 | $464.54M | 22.04% |
| 2006 | $380.66M | 31.80% |
| 2005 | $288.82M | 3.17% |
| 2004 | $279.94M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 100.37% |
IN
|
